Access cutting-edge duchenne muscular dystrophy treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Access duchenne muscular dystrophy specialists in Chicago at no cost
This study follows strict safety protocols and ethical guidelines
All study-related duchenne muscular dystrophy treatment provided free
RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, tolerability, and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in participants with Duchenne. For additional information on how to participate (or be considered for the study), please follow this lin
Sponsor: REGENXBIO Inc.
Check if you qualify for this duchenne muscular dystrophy clinical trial in Chicago, IL
If you're searching for duchenne muscular dystrophy treatment options in Chicago, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced duchenne muscular dystrophy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.